Sophia Genetics SA
$ 5.72
-5.45%
24 Jul - close price
- Market Cap 479,881,000 USD
- Current Price $ 5.72
- High / Low $ 6.32 / 5.72
- Stock P/E N/A
- Book Value 0.64
- EPS -1.18
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.30 %
- ROE -1.23 %
- 52 Week High 6.77
- 52 Week Low 2.92
About
Sophia Genetics SA (SOPH) stands at the forefront of data-driven medicine, delivering advanced genomic and clinical data analytics that significantly enhance patient outcomes. Utilizing cutting-edge machine learning technologies, the company provides an integrated platform designed to help healthcare providers navigate complex genomic data, facilitating personalized treatment strategies in oncology, rare diseases, and hereditary conditions. With a robust global footprint and strategic partnerships with leading healthcare organizations, Sophia Genetics is well-positioned to transform the precision medicine landscape and solidify its role as a key player in the genomics industry.
Analyst Target Price
$9.00
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.15 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SOPH
2026-07-26 12:11:53
This article provides the quarterly and annual cash flow statements for Sophia Genetics SA (SOPH), including operating, investing, and financing cash flows, along with related frequently asked questions. It details key financial figures such as net income, capital expenditures, and free cash flow over various fiscal quarters and years.
2026-07-23 12:11:18
SOPHiA GENETICS SA (NASDAQ:SOPH) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $9.00. While the company's latest quarterly revenue exceeded estimates, it reported a wider-than-expected loss and is still projected to remain unprofitable this year. Insiders have recently sold shares, but institutional investors have increased their holdings, and the company is set to report its Q2 2026 results on August 4th.
2026-07-23 11:10:30
Zacks Research upgraded SOPHiA GENETICS (NASDAQ:SOPH) to a "Hold" rating, though the stock has been trading down 1.5% near its 52-week high. Despite some positive sentiment from other analysts regarding its long-term growth and potential profitability by FY2028, the company continues to post weak fundamentals, including an EPS miss and projected losses for 2026 and 2027. Insiders have also been selling shares, highlighting ongoing financial challenges for the data-driven medicine company.
2026-07-22 11:41:04
HC Wainwright has reiterated a "Buy" rating and a $12.00 price target for SOPHiA GENETICS (NASDAQ:SOPH), estimating a Q2 2026 loss of $0.15 per share. The firm projects profitability for SOPHiA GENETICS by FY2028. Despite missing Q2 2026 EPS expectations at $(0.27), the company exceeded revenue forecasts with $21.69 million.
2026-07-22 03:10:33
SOPHiA GENETICS announced it will release its second quarter 2026 financial results on Tuesday, August 4, 2026, before U.S. markets open. The company will host a conference call at 8:00 a.m. EDT to discuss the results and business outlook, which will also be webcast live on its Investor Relations Website. SOPHiA GENETICS (Nasdaq: SOPH) is an AI-native healthcare technology company focused on data-driven medicine.
2026-07-22 02:09:43
SOPHiA GENETICS (Nasdaq: SOPH) announced it will release its second quarter 2026 financial results before U.S. markets open on Tuesday, August 4, 2026. The company will host a conference call on the same day at 8:00 a.m. EDT / 2:00 p.m. CET to discuss the results and business outlook. A live webcast and replay of the call will be available on the SOPHiA GENETICS Investor Relations Website.
